Evotec

Evotec ROE

The Return on Equity (ROE) of Evotec (EVT.DE) as of Nov 20, 2026 is -12.72 %. In the previous year, Return on Equity (ROE) was -20.59 % — a change of -38.20% (higher).

ROE

-12.72 %

YoY

-38.20%

Last updated:

In 2025, Evotec's return on equity (ROE) was -12.72 %, a -38.20% increase from the -20.59 % ROE in the previous year.

The Evotec ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
19.85 EUR
Jan 1, 2019
8.00 EUR
Jan 1, 2020
0.87 EUR
Jan 1, 2021
15.64 EUR
Jan 1, 2022
-14.80 EUR
Jan 1, 2023
-7.49 EUR
Jan 1, 2024
-20.59 EUR
Jan 1, 2025
-12.72 EUR
The Evotec ROE history
YEARROEYoY
-12.72 %-38.20%
-20.59 %+174.73%
-7.49 %-49.36%
-14.80 %-194.59%
15.64 %+1,705.13%
0.87 %-89.17%
8.00 %-59.71%
19.85 %+170.69%
7.33 %-43.25%
12.92 %+45.14%
8.90 %-302.08%
-4.41 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Evotec Stock analysis

What does Evotec do? Evotec SE is a biotechnology company based in Hamburg that specializes in the development of drug compounds for the pharmaceutical and biotech industries. The company was founded in 1993 as part of a research project at the University of Hamburg and has since become one of the leading drug discovery and development companies globally. Evotec's business model is based on collaborating with its customers, primarily large pharmaceutical companies, to develop new and innovative drugs. Evotec offers its extensive expertise in drug discovery and acts as a service provider. The company has modern laboratories equipped with state-of-the-art scientific methods and technologies. Customers benefit from the scientists' years of experience and collaboration with renowned academic institutions worldwide. Evotec operates in the Discovery, Development, and Manufacturing segments, providing a wide range of services to its customers. In the Discovery segment, the focus is on identifying drug candidates and preclinical development of drugs using advanced technologies and research methods. In the Development segment, Evotec supports its customers in the planning, execution, and analysis of clinical trials. The close collaboration with customers allows Evotec's scientists to respond quickly and effectively to feedback and requirements. The Manufacturing segment involves the industrial production of drugs. Evotec offers a broad range of products, including both its own and customer-requested drug compounds. One example is the drug DiaPep277 for the treatment of Type 1 diabetes. DiaPep277 was developed by Evotec in collaboration with Israeli company Andromeda Biotech and is now distributed by Teva Pharmaceuticals. Another example is the drug EVT307, which was developed by Evotec in collaboration with pharmaceutical company Boehringer Ingelheim and is currently being tested in Phase II clinical trials for the treatment of schizophrenia. Evotec's success is also based on its expertise in the production of small molecules. Small molecules are drug compounds characterized by their small size and highly specific binding to target proteins. In contrast, the production of large molecules such as antibodies or biologics is more complex and expensive in development due to their size. Evotec's success story continues: In 2019, the company achieved record results, increasing its revenue by 23 percent to 446.4 million euros. The number of employees has also steadily grown in recent years and now exceeds 3,000 employees worldwide. Evotec is considered one of the most successful biotechnology companies in Europe today. Evotec is one of the most popular companies on Eulerpool.

ROE Details

Decoding Evotec's Return on Equity (ROE)

Evotec's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Evotec's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Evotec's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Evotec’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Evotec stock

Return on Equity (ROE) of Evotec is -12.72 % in 2025.

Return on Equity (ROE) of Evotec changed from -20.59 % to -12.72 %, representing a -38.20% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Evotec since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Evotec with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Evotec

All Key Metrics — Evotec